• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Future Directions: Addressing Persistent Challenges in Fibrosis Care

Opinion
Video

Panelists discuss that improving outcomes for patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) requires multifaceted efforts including developing patient-centered clinical measures, managing comorbidities, leveraging digital health tools for real-time monitoring, and addressing health equity to ensure timely, personalized care that truly reflects patients’ lived experiences.

Improving outcomes for patients with IPF and PPF requires a multifaceted approach that goes beyond just developing new drugs. A key need is reliable, easy-to-understand measures that reflect how patients actually feel and function—not just lab values or imaging. Understanding what truly causes symptoms like shortness of breath is critical, since current treatments may only make small improvements that patients don’t fully sense. Developing clinical end points that capture meaningful symptom relief would help patients recognize real benefits and increase confidence in therapies. Building muscle, addressing nutrition, and encouraging exercise are also important factors that affect patients’ overall well-being.

Alongside better clinical measures, addressing comorbidities and the broader patient experience is vital. Patients often face multiple health challenges, and managing these alongside fibrotic lung disease can improve quality of life and longevity. Education and motivation play big roles too—helping patients avoid a sense of helplessness and empowering them to take control can lead to better outcomes. Advances in digital health, such as algorithms that quantify fibrosis extent from imaging and tools for virtual monitoring, are promising ways to provide objective feedback and track disease progression in real time. This can help patients and providers make more informed decisions about when to intervene and how to optimize treatment.

Finally, improving outcomes depends on a systems-level approach that addresses health inequities and access to care. Reducing environmental risks, promoting healthy lifestyles, and ensuring rapid, equitable access to diagnostics and medications are essential. Biomarkers that reliably identify patients at risk for progression—or those who are stable—would transform care by enabling timely, personalized treatment decisions. By combining these advances in measurement, patient support, and health care delivery, the field can move toward truly meaningful improvements in the lives of people living with IPF and PPF.

Related Videos
1 expert in this video
4 experts in this video
1 expert in this video
4 experts in this video
© 2025 MJH Life Sciences
AJMC®
All rights reserved.